NCT00642889View on ClinicalTrials.gov

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

PHASE3CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

July 31, 2007

Conditions
Parkinson's Disease
Interventions
DRUG

Safinamide

DRUG

Safinamide

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT00642889 - Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension) | Biotech Hunter | Biotech Hunter